Martin F Fey
Overview
Explore the profile of Martin F Fey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Knop S, Szarejko M, Grzasko N, Bringhen S, Trautmann-Grill K, Jurczyszyn A, et al.
EJHaem
. 2024 Oct;
5(5):940-950.
PMID: 39415900
MP0250 is a designed ankyrin repeat protein that specifically inhibits both vascular endothelial growth factor A (VEGF-A) and hepatocyte growth factor (HGF), aiming at potentiating cancer therapy by disrupting the...
2.
Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials
Fey M, OReilly S, Awada A, Crowley J, Gelmon K
Curr Opin Oncol
. 2024 Aug;
36(5):418-420.
PMID: 39106404
No abstract available.
3.
Eychmuller S, Zwahlen S, Fliedner M, Juni P, Aebersold D, Aujesky D, et al.
Palliat Med
. 2021 Apr;
35(6):1108-1117.
PMID: 33908288
Background: International oncology societies recommend early palliative care. Specific models to integrate early palliative care efficiently into clinical practice are debated. The authors designed a study to look at the...
4.
5.
Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, et al.
ESMO Open
. 2016 Nov;
1(5):e000097.
PMID: 27843641
The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) are publishing a new edition of the ESMO/ASCO Global Curriculum (GC) thanks to contribution of...
6.
Rothschild S, Gautschi O, Batliner J, Gugger M, Fey M, Tschan M
Lung Cancer
. 2016 Jul;
107:73-83.
PMID: 27372519
Objectives: Src tyrosine kinase inhibitors (TKIs) significantly inhibit cell migration and invasion in lung cancer cell lines with minor cytotoxic effects. In clinical trials, however, they show modest activity in...
7.
Wampfler J, Federzoni E, Torbett B, Fey M, Tschan M
Leuk Res
. 2016 Jan;
41:96-102.
PMID: 26740055
The RNA binding proteins RBM binding motif protein 38 (RBM38) and DEAD END 1 (DND1) selectively stabilize mRNAs by attenuating RNAse activity or protecting them from micro(mi)RNA-mediated cleavage. Furthermore, both...
8.
Wampfler J, Federzoni E, Torbett B, Fey M, Tschan M
J Leukoc Biol
. 2015 May;
98(3):357-63.
PMID: 25990244
Successful myeloid differentiation depends on the expression of a series of miRNAs. Thus, it is hardly surprising that miRNAs are globally repressed in AML, a disease mainly characterized by a...
9.
Federzoni E, Gloor S, Jin J, Shan-Krauer D, Fey M, Torbett B, et al.
Leuk Res Rep
. 2015 May;
4(1):32-5.
PMID: 25984443
In an mRNA profiling screen performed to unveil novel mechanisms of leukemogenesis, we found that the sentrin-specific protease 5 (SENP5) was significantly repressed in clinical acute myeloid leukemia when compared...
10.
Fey M
Ther Umsch
. 2014 Dec;
71(12):765-70.
PMID: 25447092
Modern oncology has much to offer, and the prognosis of cancer patients has undoubtedly improved over the last few decades. Nevertheless, medical and economic toxicities of modern cancer medicine demand...